Effectiveness of IRK-19® on Body Weight Control
Not Applicable
Completed
- Conditions
- OverweightMetabolic Syndrome
- Interventions
- Dietary Supplement: Pumpkin seed extract (IRK-19)
- Registration Number
- NCT05542160
- Lead Sponsor
- Greenyn Biotechnology Co., Ltd.
- Brief Summary
This randomized, double-blind, placebo-controlled, and parallel clinical study aims to investigate the effectivness of a pumpkin seed extract (IRK-19®) on weight management.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- BMI: 25-30 kg/m2
- Waistline circumference: ˃ 80 cm
Exclusion Criteria
- Pregnant women or preparing for pregnancy.
- Lactating women.
- Women gave birth 6 months before the study.
- Subject uses diuretic, corticosteroids, anti-depressant medications, or antipsychotic medications.
- Subject has undertaken obesity-related surgeries within one year prior to the study or other surgeries within six months prior to the study.
- Change of body weight of subject is over 5% within 3 months before the study.
- Subject has serious diseases (e.g., cardiovascular diseases).
- Cancer patient.
- Subject has engaged in another study within 3 months before the study.
- Subject uses another dietary supplement related to weight management during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Pumpkin seed extract (IRK-19) Placebo capsule Treatment Pumpkin seed extract (IRK-19) IRK-19 capsule
- Primary Outcome Measures
Name Time Method Biochemistry Week 12 Insulin
Anthropometric measurement Week 12 Hip circumference
Body composition analysis Week 12 Subcutaneous fat
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
WanFang Hospital
🇨🇳Taipei City, Taiwan